Clinical Insights

FDA Approves Lembaz (Adrabetadex) for Niemann Pick Type C

FDA Approves Lembaz (Adrabetadex) for Niemann Pick Type C

The US Food and Drug Administration (FDA) has approved Lembaz (adrabetadex) for the treatment of infantile-Niemann Pick disease type C (NPC). NPC is a complex lysosomal storage disorder mainly characterized by the accumulation of unesterified cholesterol in lysosomes....

Sanofi’s Orphan Drug Supply Update | The CheckRare Brief Special Edition

Sanofi’s Orphan Drug Supply Update | The CheckRare Brief Special Edition

On this special edition of the CheckRare Brief, we talk with Alaa Hamed, Sanofi’s Global Head of Medical Affairs for Rare Diseases, and Maite Durrenbach, Head of Specialty Care Manufacturing and Supply at Sanofi, about the company’s current supply chain problems for some of their biological therapies.

More

Highlights from The Liver Meeting 2026 | The CheckRare Brief

In this episode, we discuss highlights from The Liver Meeting, Ultragenyx program cuts, and ANI Pharmaceuticals’ offer to buy Egetis Therapeutics.     Ultragenyx Ends Angelman Syndrome and...

3D Printed Treatment Options | The CheckRare Brief

In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options.       New...

Rational Design Meets Real-World Relevance: Pegunigalsidase Alfa in the Treatment of Fabry Disease

Rational Design Meets Real-World Relevance: Pegunigalsidase Alfa in the Treatment of Fabry Disease

Experts examine advances in rational drug design, focusing on pegunigalsidase alfa and its emerging role in patient care for Fabry disease.

Recent Videos

Social Wall

International Rett Syndrome Foundation Works to Advance Research and Support Families

Three-Year Study Finds Burosumab Improves Symptoms in Adults With X-Linked Hypophosphatemia

Dr. Joshua Zeidner explains the REVEAL-ND clinical trial enrolling patients with newly diagnosed, previously untreated NPM1-mutated AML.

For more information on trial design, enrollment, and outcomes, view the full interview at Read morehttps://checkrare.com/revumenib-chemotherapy-in-newly-diagnosed-aml-with-npm1-mutation-phase-3-reveal-nd-study/

#AML #AcuteMyeloidLeukemia

Trutakna Meets All Prespecified Endpoints in Phase 3 ORIGIN 3 Trial in IgA Nephropathy

Trutakna Meets All Prespecified Endpoints in Phase 3 ORIGIN 3 Trial in IgA Nephropathy

The Need for Earlier Pulmonary Hypertension Screening in Interstitial Lung Disease

New research is helping advance the understanding and treatment of rare kidney diseases.

The VALIANT study evaluated pegcetacoplan, a targeted complement therapy, in patients with C3G and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

Explore the